Acta medica OkayamaMay 1, 2009

How a specific region in ADAMTS1 controls the stability of its mRNA

mRNA Technology Weekly Brief ↗PubMed ↗DOI ↗

Updated Mar 20, 2026

Abstract

ADAMTS1 mRNA levels peaked 6 hours after stimulation with TNF-alpha.

Expression of ADAMTS1 mRNA rapidly increases following stimulation with TNF-alpha.
After peaking at 6 hours, ADAMTS1 mRNA levels decrease.
The 3'-untranslated region (UTR) of ADAMTS1 mRNA contains elements that may influence its stability.
The addition of actinomycin D indicated that ADAMTS1 mRNA decays after TNF-alpha stimulation.
AUUUA motifs within the ADAMTS1 3'-UTR were associated with destabilization of mRNA in experiments.

Simplified

ADAMTS1 (a disintegrin and metalloproteinase with thrombospondin motifs 1) is an inflammatory-induced gene. We have previously reported that ADAMTS1 was strongly but transiently expressed in the infarcted heart. In this study, we investigated whether a 3'-untranslated region (UTR) affects the mRNA stability of this gene. When stimulated with tissue necrosis factor (TNF)-alpha, the expression level of ADAMTS1 mRNA rapidly increased, but the induction of ADAMTS1 mRNA peaked at 6h after stimulation, after which the expression levels of ADAMTS1 mRNA decreased. The 3'-UTR ADAMTS1 mRNA contains multiple adenine and uridine-rich elements, suggesting that the 3'-UTR may regulate gene stability. The addition of actinomycin D, an RNA synthesis inhibitor, demonstrated the decay of induced ADAMTS1 mRNA by TNF-alpha. Furthermore, a region containing multiple AUUUA motifs within the ADAMTS1 3'-UTR destabilized transfected Enhanced Green Fluorescence Protein (EGFP) mRNA expression. These results demonstrated that the ADAMTS1 3'-UTR may regulate the expression of ADAMTS1 mRNA.

How a specific region in ADAMTS1 controls the stability of its mRNA

Abstract

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the mrna technology brief

Abstract

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the mrna technology brief